Funder
GuangXi University of Chinese Medicine
Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Reference55 articles.
1. China cardiovascular diseases report 2018: an updated summary;Ma;J Geriatr Cardiol,2020
2. Risk factors associated with recurrence within 90 days of ischemic stroke onset in Chinese medicine hospital: a national cross-sectional study in China;Gao;World J Tradit Chin Med,2020
3. Ginsenoside Rb1 pretreatment attenuates myocardial ischemia by reducing calcium/calmodulin-dependent protein kinase II-medicated calcium release;Zhang;World J Tradit Chin Med,2020
4. A novel danshensu-tetramethylpyrazine conjugate DT-010 provides cardioprotection through the PGC-1α/Nrf2/HO-1 pathway;Zhang;Biol. Pharm. Bull.,2017
5. Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway;Hu;Int. J. Mol. Med.,2016